Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
Highest Quality | For Research Use Only

Tesamorelin

Tesamorelin Japan Peptide

Tesamorelin, a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), has been widely studied for its potential therapeutic applications, particularly in the context of HIV-associated lipodystrophy (HALS). It consists of 44 amino acids and functions by stimulating the pituitary gland to produce and secrete growth hormone (GH).

According to research, Tesamorelin can significantly reduce visceral adipose tissue (VAT) leading to improved lipid profiles and insulin sensitivity, suggesting potential benefits for cardiovascular health.

Tesamorelin has also been shown to increase IGF-1 (Insulin-like Growth Factor 1) levels, which Japan research suggests is beneficial for muscle growth, recovery, and overall metabolic function.

Showing all 5 results

Potential Benefits of Tesamorelin Peptide

  • Visceral Fat Reduction: Tesamorelin, a growth hormone-releasing hormone analogue, has been shown in research to significantly decrease visceral adipose tissue in people living with HIV [1]. This reduction in visceral fat is associated with improvements in metabolic markers including triglycerides and adiponectin levels [2].
  • Improvement in Fat Quality: According to research studies, independent of changes in fat quantity, Tesamorelin has been found to improve fat quality in patients living with HIV over 26-52 weeks of treatment [3].
  • Management of HIV-Associated Lipodystrophy: Tesamorelin is the first and only treatment indicated specifically for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy [4].
  • Impact on Liver Health: Research suggests that reductions in visceral adipose tissue (VAT) with Tesamorelin have been associated with changes in alanine aminotransferase (ALT), suggesting potential benefits for liver health [5].
  • Inflammatory Markers: According to studies, in HIV patients with abdominal adiposity, tesamorelin may have a beneficial effect on adiponectin and fibrinolytic markers in association with changes in VAT [6].
  • Metabolic Effects: Tesamorelin has demonstrated in research studies an ability to reduce abdominal adiposity in viscerally obese subjects with HIV lipodystrophy [7].
  • Increased Insulin Sensitivity: In healthy men, tesamorelin has been found in studies to impact endogenous GH pulsatility and insulin sensitivity positively [8].

References

[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6766405/

[2] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4601733/

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC8243807/

[4] https://pubmed.ncbi.nlm.nih.gov/ 21668043/

[5] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC5633509/

[6] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3673013/

[7] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3513535/

[8] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3038486/

 

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://japan.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.